Related Concept Videos
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:17Other Pulmonary Disorders
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:21Acute Respiratory Failure-II
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
01:30Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
Predictive role of natural killer cells in bronchoalveolar lavage fluid of patients with sarcoidosis.
Pulmonology·2024
Same author
[Linguistic Validation of the "German Lung Fibrosis Health Related Quality of Life Questionnaire"].
Pneumologie (Stuttgart, Germany)·2021
Same author
[Cortisone-free rheumatology-Distant vision or clinical routine soon?]
Zeitschrift fur Rheumatologie·2021
Same author
[S2k guidelines: management of large-vessel vasculitis].
Zeitschrift fur Rheumatologie·2020
Related Experiment Video
Updated: Jun 18, 2026
06:03
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
[Pulmonary fibrosis].
A Prasse1, J U Holle, J Müller-Quernheim
1Abteilung für Pneumologie, Universitätsklinikum Freiburg, Killianstrasse 5, 79106 Freiburg, Deutschland. antje.prasse@uniklinik-freiburg.de
Der Internist
|December 4, 2009
Summary
Pulmonary fibrosis, a progressive lung disease, involves connective tissue buildup and lung damage, often linked to rheumatic diseases. While treatments for fibrotic remodeling are lacking, immunosuppression can help manage inflammatory causes.
Area of Science:
- Pulmonology
- Rheumatology
- Pathology
Context:
- Pulmonary fibrosis is a progressive lung disease characterized by interstitial connective tissue accumulation.
- Its prevalence is increasing, particularly in older individuals.
- Rheumatic diseases are associated with approximately half of all pulmonary fibrosis cases.
Purpose:
- To define pulmonary fibrosis and its pathological characteristics.
- To outline the revised classification of interstitial pneumonia.
- To discuss current treatment limitations and strategies.
Summary:
- Pulmonary fibrosis involves diffuse connective tissue accumulation in the lung's interstitial space, leading to parenchymal destruction.
- A 1998 revision defined six types of interstitial pneumonia based on distinct pathological patterns.
- No definitive treatment resolves fibrotic lung remodeling, but immunosuppressive therapies are used for inflammatory-induced pulmonary fibrosis.
Impact:
- Highlights the need for effective treatments for fibrotic lung remodeling.
- Emphasizes the link between rheumatic diseases and pulmonary fibrosis.
- Provides an updated classification framework for interstitial pneumonias.